Murphy Andrew J sold 74 shares of REGENERON PHARMACEUTICALS, INC. at $950.61 for −$70.3k on Nov 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Co-Chief Scientific Officer
Co-Chief Scientific Officer
Filed Nov 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$70,345.14Shares × reported price
Shares traded
74Common Stock
Price per share
$950.61Reported price. Read footnotes for ranges.
% of reported position traded
0.14%This security and ownership context
Holdings after
51,623Direct
Trade date
Nov 17, 2026Sell
Filed
Nov 18, 2026, 4:07 PM ET1-day reporting delay
Accession
0001796226-26-000006Code S · Transaction 405675
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 51,697 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

REGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 25, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −3.1%1d ago +0.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026. F2: Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F3: Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F4: Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F5: Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F6: Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F7: Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F8: Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price F9: Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F10: Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F11: Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F12: Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F13: Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F14: Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F15: Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F16: Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F17: The stock option award vested in four equal annual installments, commencing one year after the date of grant.